Literature DB >> 18644677

Treatment of esophageal spirocercosis with milbemycin oxime.

P J Kelly1, M Fisher, H Lucas, R C Krecek.   

Abstract

Six medium sized mixed breed dogs treated with milbemycin oxime (11.5mg on days 0, 7 and 28 and then monthly) stopped shedding Spirocerca lupi ova after 3-44 days. There was no evidence of subsequent shedding in repeated tests (about 5/dog) carried out from 31 to 133 days after initiation of treatment. Esophageal nodules disappeared in all dogs within 95-186 days and radiographic signs resolved within 85-127 days in the five dogs that were studied. This preliminary data shows milbemycin oxime deserves further evaluation for the treatment of spirocercosis.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18644677     DOI： 10.1016/j.vetpar.2008.06.012

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN： 0304-4017            Impact factor:   2.738


  4 in total

1.  Efficacy of a combination of imidacloprid 10%/moxidectin 2.5% spot-on (Advocate® for dogs) in the prevention of canine spirocercosis (Spirocerca lupi).

Authors:  Christophe Le Sueur; Sophie Bour; Roland Schaper
Journal:  Parasitol Res       Date:  2010-08-13       Impact factor: 2.289

2.  Successful resolution of esophageal granulomas in a dog infected with Spirocerca lupi.

Authors:  Hiroki Okanishi; Jun Matsumoto; Hiromi Aoki; Yumiko Kagawa; Kazushi Asano; Sadao Nogami; Toshihiro Watari
Journal:  J Vet Med Sci       Date:  2013-07-24       Impact factor: 1.267

3.  Field clinical study evaluating the efficacy and safety of an oral formulation containing milbemycin oxime/praziquantel (Milbemax®, Novartis Animal Health) in the chemoprevention of the zoonotic canine infection by Dirofilaria repens.

Authors:  Angela Di Cesare; Gabriele Braun; Emanuela Di Giulio; Barbara Paoletti; Vincenzo Aquilino; Roberto Bartolini; Francesco La Torre; Silvana Meloni; Jason Drake; Federico Pandolfi; Stefania Avolio; Donato Traversa
Journal:  Parasit Vectors       Date:  2014-07-29       Impact factor: 3.876

4.  Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study.

Authors:  Gilad Segev; Alicia Rojas; Eran Lavy; Marganit Yaffe; Itamar Aroch; Gad Baneth
Journal:  Parasit Vectors       Date:  2018-03-05       Impact factor: 3.876
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.